Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ECYT
Delisted

Endocyte Fund Price (Quote)

$23.99
+0 (+0%)
At Close: Jan 18, 2019

Range Low Price High Price Comment
30 days $23.97 $24.00 Friday, 18th Jan 2019 ECYT stock ended at $23.99. During the day the stock fluctuated 0% from a day low at $23.99 to a day high of $23.99.
90 days $23.37 $24.00
52 weeks $2.81 $24.00

Historical Endocyte prices

Date Open High Low Close Volume
Jan 28, 2016 $3.30 $3.37 $3.21 $3.34 152 700
Jan 27, 2016 $3.52 $3.52 $3.27 $3.28 267 500
Jan 26, 2016 $3.50 $3.55 $3.33 $3.52 219 800
Jan 25, 2016 $3.58 $3.64 $3.45 $3.47 251 200
Jan 22, 2016 $3.50 $3.58 $3.42 $3.58 319 100
Jan 21, 2016 $3.31 $3.50 $3.15 $3.42 719 200
Jan 20, 2016 $2.78 $2.99 $2.68 $2.93 278 000
Jan 19, 2016 $2.81 $3.00 $2.77 $2.82 221 700
Jan 15, 2016 $2.88 $2.93 $2.65 $2.93 329 800
Jan 14, 2016 $2.91 $3.06 $2.91 $2.95 527 900
Jan 13, 2016 $3.37 $3.45 $2.95 $2.97 527 700
Jan 12, 2016 $3.40 $3.49 $3.26 $3.37 270 800
Jan 11, 2016 $3.55 $3.56 $3.28 $3.32 310 900
Jan 08, 2016 $3.58 $3.65 $3.47 $3.51 296 800
Jan 07, 2016 $3.65 $3.72 $3.51 $3.57 345 200
Jan 06, 2016 $3.93 $3.93 $3.70 $3.73 380 000
Jan 05, 2016 $3.95 $3.99 $3.89 $3.91 127 900
Click to get the best stock tips daily for free!

About Endocyte

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of ad... ECYT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT